ProCE Banner Activity

0761-009: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma

Slideset Download
Conference Coverage
Mogamulizumab produces clinical response in a population of adult patients with relapsed/refractory ATL who currently have no consensus treatment options.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals